|Articles|June 1, 2020
- Pharmaceutical Executive-06-01-2020
- Volume 40
- Issue 6
Pharmaceutical Executive, June 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive June 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Pharm Exec's Top 50 Companies 2020almost 6 years ago
Better ESG Communication with Investorsalmost 6 years ago
Will the Biopharma Leaders Please Take the Stage!almost 6 years ago
Delivering Hope in a Pandemicalmost 6 years ago
The Specter of Compulsory Licensing Haunts Vaccine Debatealmost 6 years ago
Pivotal Moments: How Leaders Can Prepare for the Unexpectedalmost 6 years ago
How to Thank a Physician Post-COVID-19almost 6 years ago
Spotlight on Science Gives Public New Perspectivealmost 6 years ago
Rare Insights: Arndt Rolfs, CENTOGENEalmost 6 years ago
FDA’s Emergency Use Process Under ScrutinyNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
2
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market
3
Positioning A New Standard of Care in Relapsed Multiple Myeloma: Q&A with Imran Khan, MD, PhD
4
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
5
